Maruho Report 2023

44/60

Ratio of R&D expenses to net sales (%)24.4Total assets (Millions of yen)43201820192018201989,17185,20913.812.510,63112,347Net sales for the fiscal year ended September 2018 were 85,209 million yen. After that, sales steadily increased due mainly to the launch of new products and an increase in sales of our main products. Net sales for the fiscal year ended September 2023 totaled 96,184 million yen (up 0.8% year on year) while operating profit came in at 6,227 million yen (down 62.1%).12,7372,976In the fiscal year ended September 2023, profit attributable to owners of parent amounted to 3,866 million yen (down 51.5% year on year) due to the impact of aggressive investment activities aimed at returning to a growth trajectory.Maruho Report 202320202021202220202021202296,75495,39096,18496,18488,95422.717.213.921,94212,33316,43114,9027,9726,31878,7606.56,227In our R&D activities, we have expanded our collaboration with companies and universities in Japan and overseas to create and launch new products. This has led to the release of BEPIO Lotion for the treatment of acne vulgaris and the herpes simplex detection kit DermaQuick HSV using the immunochromatography method.* Includes Maruho’s medical devices business, self-care business, and Maruho Medical, Inc.’s medical devices business.110,478Total assets as of September 30, 2023 increased by 4,231 million yen from the previous fiscal year to 181,451 million yen. Current assets decreased by 2,584 million yen, mainly due to a decrease in cash and deposits of 10,469 million yen and an increase in merchandise and finished goods of 3,447 million yen. Fixed assets increased by 6,816 million yen, mainly due to an increase in construction in progress of 1,943 million yen and an increase in investment securities of 2,426 million yen. Total net assets increased by 4,224 million yen compared to the previous fiscal year to 156,720 million yen, mainly owing to an increase in retained earnings of 3,732 million yen.2018201920202021201820192020202187,72480,71780,84918.816.815.313,20312,27615,168164,257143,286142,908151,394142,857127,825120,21783.784.177.186,24116.114.021,03412,27313,917177,219181,451152,495156,720156,72086.385.585.820222022Net sales / Operating profit / Ratio of operating profit to net salesProfit attributable to owners of parentPharmaceutical business* net sales / R&D expenses / Ratio of R&D expenses to net salesTotal net assets / Total assets / Equity-to-asset ratioTotal net assets (Millions of yen)5. Financial Information / Company Information Financial/Non-financial HighlightsNet sales (Millions of yen)Operating profit (Millions of yen)(Millions of yen)Ratio of operating profit to net sales (%)Pharmaceutical business net sales (Millions of yen)R&D expenses (Millions of yen)Equity-to-asset ratio (%)20233,8663,866202386,29286,29220232023Financial Highlights (Consolidated) Fiscal year ended September 2023